Publicaciones en colaboración con investigadores/as de Universidad de Navarra (27)

2009

  1. Neuroprotección en la enfermedad de parkinson: Análisis a través de la metodología de informadores clave

    Neurologia, Vol. 24, Núm. 2, pp. 113-124

1997

  1. Entorhinal cortex of the rat: Cytoarchitectonic subdivisions and the origin and distribution of cortical efferents

    Hippocampus, Vol. 7, Núm. 2, pp. 146-183

1996

  1. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

    Neurology, Vol. 47, Núm. 1, pp. 219-224

  2. Consequences of nigrostriatal denervation on the γ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes

    Neurology, Vol. 46, Núm. 3, pp. 802-809

  3. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease

    PARKINSON'S DISEASE

  4. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.

    Advances in neurology, Vol. 69, pp. 209-216

  5. Is dopaminergic cell death accompanied by concomitant nerve plasticity?

    PARKINSON'S DISEASE

  6. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: A cytochrome oxidase histochemistry study

    Neuroscience, Vol. 71, Núm. 4, pp. 903-912

  7. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis

    Brain, Vol. 119, Núm. 5, pp. 1717-1727

1995

  1. Chronic alcoholism decreases neuronal nuclear size in the human entorhinal cortex

    Neuroscience Letters, Vol. 183, Núm. 1-2, pp. 71-74

  2. Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNA

    European Journal of Neuroscience, Vol. 7, Núm. 6, pp. 1199-1209

  3. Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain

    Experimental Neurology, Vol. 131, Núm. 1, pp. 108-113

1994

  1. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy

    Annals of Neurology, Vol. 36, Núm. 2, pp. 206-214

  2. Letters to the editor

    Movement Disorders

  3. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration

    Neuroscience Letters, Vol. 175, Núm. 1-2, pp. 121-125

1993

  1. Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum

    Brain Research, Vol. 624, Núm. 1-2, pp. 281-285

  2. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?

    Neuroscience, Vol. 56, Núm. 2, pp. 499-511

  3. GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys

    Neuroscience, Vol. 56, Núm. 4, pp. 965-972

  4. Origin of chorea‐ballism and multisystem degeneration: Pathophysiological implications

    Movement Disorders, Vol. 8, Núm. 1, pp. 123-124

1992

  1. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset

    Brain Research, Vol. 585, Núm. 1-2, pp. 156-160